Warren A. Kaplan, PhD, JD, MPH
Clinical Assistant Professor, Global Health - Boston University School of Public Health
Biography
Warren A. Kaplan, PhD, JD, MPH is a Clinical Assistant Professor in the Department of Global Health at the Boston University School of Public Health, where he is a member of the World Health Organization Collaborating Center in Pharmaceutical Policy. His research focuses on pharmaceutical and legal policies related to health system strengthening and evaluations of medicines access and utilization.
His current interests and expertise include intellectual property policy, antimicrobial resistance, medicines price analysis, generic medicines policies, quality use of medicines, access to medicines for non-communicable diseases and the role of the private sector to promote equitable access and efficient use of medicines in low and middle income countries. Dr. Kaplan has carried out cross-national comparison of medicines consumption and trade using sales and customs data bases to inform policy making about adequate use of insulin and other essential medicines.
Between 1995 and 2001 he was Assistant General Counsel at Biogen, the pharmaceutical company in Cambridge Massachusetts and coordinated and established Biogen's worldwide patent filings and all intellectual property related activities for: Biogen's FDA approved psoriasis drug, including negotiating settlement of trademark disputes and collaborative R&D agreements between Biogen and third parties totaling about $100 M . He initiated and prepared due diligence reviews for 30 business opportunities and was responsible for $50-60M per year of Biogen's R&D budget and advised Biogen on global intellectual property strategies.
Between 2003-2004 Dr. Kaplan was Technical Officer at the World Health Organization Geneva, Switzerland in the Essential Drugs & Medicine/Policy, Access, Rational Use Priority Medicines Project. This was a $500,000 Dutch funded project given to the WHO which was designed to advise the European Union on best priorities for pharmaceutical R&D for the 7th EU Framework Program. Dr. Kaplan developed the methodology for uncovering research and market "gaps" in treatment for high and medium burden diseases and prepared several “state of the art" reviews of pharmaceutical "gaps" for cancer, HIV/AIDS, alcoholic liver disease, chronic obstructive pulmonary disease. Between 2007-2009, he also served as a WHO Technical Officer for the Priority Medical Devices Project- a $1,000,000 Dutch funded project given to the WHO- designed to advise the European Union on best priorities for R&D and access to medical devices in developing countries. Dr. Kaplan also helped to developed survey methodologies for uncovering research and market "gaps" in development and use of medical devices for high and medium burden diseases.
He has worked as a technical adviser for various international organizations, among them the Doctors Without Borders, the Clinton Foundation, the Alliance for Health Systems and Policy Research, Health Action International. He has published widely in international peer review journals in science, law and public health such as Nature, The Lancet, World Health Organization Bulletin, Health Policy and Planning, Health Policy, PloS One, Tropical Medicine and International Health. He received his training as an ecologist and microbiologist from Boston University, his post-doctoral training in biogeochemistry from Harvard University, his law degree from Suffolk University and his MPH from Boston University.
Education
- Boston University, PhD Field of Study: Biology
- Suffolk University, JD Field of Study: Law
- Boston University School of Public Health, MPH Field of Study: International Health
- Texas A&M University, MS Field of Study: Oceanography
- Queens College, City University of New York, BA Field of Study: Biology
Websites
Classes Taught
- SPHGH885
- SPHPH740
- SPHPM740
Publications
- Published on 9/1/2023
Thrasher R, Kaplan W, Wirtz VJ, Clear L, Bodduluri SP, Polaski S. Policy responses to COVID-19: lessons for the global trade and investment regime. Global Health. 2023 Sep 01; 19(1):66. PMID: 37658444.
Read At: PubMed
- Published on 5/2/2023
Kaplan WA, Cellini CM, Eghan K, Pilz K, Harrison D, Wirtz VJ. Contracting retail pharmacies as a source of essential medicines for public sector clients in low- and middle-income countries: a scoping review of key considerations, challenges, and opportunities. J Pharm Policy Pract. 2023 May 02; 16(1):60. PMID: 37131256.
Read At: PubMed
- Published on 3/7/2023
Lin PY, Kaplan W, Lin CH, Lee YH. Taiwan's National Health Insurance at the Emergency Department following the COVID-19 outbreak. Public Health Nurs. 2023; 40(4):517-527. PMID: 36882994.
Read At: PubMed
- Published on 12/12/2022
Polaski S, Thrasher R, Wirtz VJ, Kaplan WA . BU Global Development Policy Center. Can the World Trade Organization Survive a Polarizing World? Three Possible Futures for the Global Trade and Investment Regime . 2022.
- Published on 10/1/2022
Beall RF, Glazer T, Ahmad H, Buell M, Hahn S, Houston AR, Kesselheim AS, Nickerson JW, Kaplan W. Patent "Evergreening" of Medicine-Device Combination Products: A Global Perspective. Healthc Policy. 2022 Oct; 18(2):14-26. PMID: 36495532.
Read At: PubMed
- Published on 9/16/2022
Serván-Mori E, Islam MD, Kaplan WA, Thrasher R, Wirtz VJ. Out-of-pocket expenditure on medicines in Bangladesh: An analysis of the national household income and expenditure survey 2016-17. PLoS One. 2022; 17(9):e0274671. PMID: 36112592.
Read At: PubMed
- Published on 1/1/2022
Beall, RF, Glazer T, Ahmad H, Buell M, Hahn S, Houston A, Kesselheim A, Nickerson JW, Kaplan, W. Patent “Evergreening” of Medicine-Device Combination Products: A Global Perspective. Healthcare Policy. 2022; 2(18):14-26.
- Published on 11/1/2021
Rachel D. Thrasher, Sandra Polaski, Warren A. Kaplan, Louise Clear, Shiva Priya Bodduluri, Veronika J. Wirtz. Global Development Policy Center Report. 2021.
Read At: Custom
- Published on 7/29/2021
Sharma A, Kaplan WA. Insulin imports fail to meet many countries' needs. Science. 2021 07 30; 373(6554):494-497. PMID: 34326225.
Read At: PubMed
- Published on 5/18/2021
Sharma A, Kaplan WA, Satheesh G, Poudyal IP, Gyawali P, Neupane D, Bhandari PM, Malla M, Sapkota S, Mishra SR. Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal. Glob Heart. 2021 05 18; 16(1):38. PMID: 34040951.
Read At: PubMed
View 68 more publications:View Full Profile at BUMC
News & In the Media
- Published on September 1, 2021
-
Published on May 14, 2021
COVID-19 Vaccine Inequity: The Debate over Patent Waivers Intensifies
- Published on August 1, 2019
-
Published on July 29, 2019
Drug Prices: Trump Trade Deal Would Boost Prescription Prices
- Published on June 24, 2019
-
Published on February 11, 2019
Rising Price Has Pushed Insulin out of Reach for Some People
- Published on April 5, 2018
-
Published on January 31, 2017
More Work Needed to Reduce Prices, Increase Availability of Locally Produced Medicines
- Published on January 18, 2017
-
Published on October 14, 2016
Access to Insulin in India Constrained by Costs, Lack of Market Competition
- Published on March 28, 2016
-
Published on April 17, 2015
New Public Vaccination Programs in India Face Similar Obstacles as Private Vaccination